5 unchanged sentences
001-39536), filed with the Securities and Exchange Commission on September 29, 2020).
−Removed: Amendment No.
−Removed: 1 to Sales Agreement, dated March 30, 2022, by and among the Company, Goldman Sachs & Co.
−Removed: LLC, SVB Securities LLC and Wells Fargo Securities, LLC (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K (File No.
−Removed: 001-39536), filed with the Securities and Exchange Commission on June 30, 2022).
+Added: Option Agreement, by and between the Company and Astellas, dated October 21, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-39536), filed with the Securities and Exchange Commission on October 31, 2022).
+Added: Securities Purchase Agreement, by and between the Company and Astellas, dated October 21, 2022 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-39536), filed with the Securities and Exchange Commission on October 31, 2022).
+Added: Registration Rights Agreement, by and between the Company and Astellas, dated October 21, 2022 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-39536), filed with the Securities and Exchange Commission on October 31, 2022).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
+Added: Certain schedules to this agreement have been omitted in accordance with Item 601(b)(2) of Regulation S-K.
+Added: A copy of any omitted schedules will be furnished supplementally to the SEC upon request.
+Added: Portions of this document (indicated by “[***]” have been omitted because they are not material and are the type that Taysha Gene Therapies, Inc.
+Added: treats as private and confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Taysha Gene Therapies, Inc.
−Removed: August 11, 2022
+Added: November 8, 2022
/s/ RA Session II
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 11, 2022
+Added: November 8, 2022
/s/ Kamran Alam
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.